Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423478 | 1.00 | CXCR2 (0.74) | CXCR2CCR6 | |
| SCHEMBL2300081 | 0.95 | CXCR2 (0.70) | CXCR2CCR6 | |
| SCHEMBL2300075 | 0.95 | CXCR2 (0.70) | CXCR2CCR6 | |
| SCHEMBL2298386 | 0.94 | CXCR2 (0.69) | CXCR2CCR6 | |
| SCHEMBL2299001 | 0.92 | CXCR2 (0.67) | CXCR2CCR6 | |
| SCHEMBL2293247 | 0.92 | CXCR2 (0.67) | CXCR2CCR6 | |
| SCHEMBL2293856 | 0.92 | CXCR2 (0.67) | CXCR2CCR6 | |
| SCHEMBL2297361 | 0.92 | CXCR2 (0.69) | CXCR2CCR6 | |
| SCHEMBL1579828 | 0.92 | CXCR2 (0.71) | CXCR2CCR6 | |
| SCHEMBL2300378 | 0.92 | CXCR2 (0.71) | CXCR2CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710053-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2020-09-23 | — | — | EP | claimed |
| CN-111655288-A | Combination therapy | 诺华股份有限公司 | 2020-09-11 | — | — | CN | claimed |
| US-20200277378-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-09-03 | — | — | US | claimed |
| EP-3287438-A1 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | Novartis AG (CH) | 2018-02-28 | — | — | EP | claimed |
| EP-2760821-B1 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | claimed |
| US-9018261-B2 | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | NOVARTIS AG (CH) | 2015-04-28 | — | — | US | claimed |
| EP-2760821-A1 | CHOLINE SALT OF AN ANTI - INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | Novartis AG (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20140206768-A1 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | claimed |
| EP-2310359-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-15 | — | — | EP | claimed |
| WO-2013030803-A1 | CHOLINE SALT OF AN ANTI - INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | NOVARTIS AG (CH) | 2013-03-07 | — | — | WO | claimed |
| US-8288588-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2012-10-16 | — | — | US | claimed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | claimed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| WO-2010015613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | CXCR2 219/4885CCR6 137/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CXCR2 67/4885CCR6 141/4885 |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885CCR6 57/4885 |
| US-20200277378-A1 | COMBINATION THERAPIES | CSF3R, CSF1R, IL1RN | CXCR2 10/4885CCR6 58/4885 |
| US-20100029670-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CCR6 30/4885 |
| US-20140206768-A1 | CHOLINE SALT OF AN ANTI-INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUND | CHKB, CHKA, BCHE | CXCR2 1104/4885CCR6 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.